Wall Street Zen downgraded shares of Nektar Therapeutics (NASDAQ:NKTR – Free Report) from a hold rating to a sell rating in a research report report published on Sunday morning.
A number of other equities analysts have also commented on NKTR. HC Wainwright lifted their price target on shares of Nektar Therapeutics from $135.00 to $165.00 and gave the company a “buy” rating in a research report on Tuesday, February 10th. BTIG Research upped their price objective on shares of Nektar Therapeutics from $118.00 to $151.00 and gave the stock a “buy” rating in a report on Tuesday, February 10th. Jefferies Financial Group reiterated a “buy” rating on shares of Nektar Therapeutics in a research note on Wednesday, December 17th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Nektar Therapeutics in a report on Monday, December 29th. Finally, Piper Sandler reissued an “overweight” rating and set a $105.00 target price on shares of Nektar Therapeutics in a research report on Monday, January 26th. Nine analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $128.13.
Get Our Latest Stock Report on Nektar Therapeutics
Nektar Therapeutics Stock Performance
Nektar Therapeutics (NASDAQ:NKTR – Get Free Report) last issued its quarterly earnings data on Thursday, March 12th. The biopharmaceutical company reported ($1.78) earnings per share for the quarter, beating analysts’ consensus estimates of ($2.69) by $0.91. Nektar Therapeutics had a negative return on equity of 386.16% and a negative net margin of 297.07%.The business had revenue of $21.81 million for the quarter, compared to the consensus estimate of $10.44 million. On average, research analysts predict that Nektar Therapeutics will post -0.72 earnings per share for the current year.
Insider Buying and Selling
In related news, CEO Howard W. Robin sold 423 shares of the business’s stock in a transaction on Wednesday, February 18th. The shares were sold at an average price of $73.00, for a total transaction of $30,879.00. Following the transaction, the chief executive officer owned 75,489 shares of the company’s stock, valued at approximately $5,510,697. The trade was a 0.56% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, insider Jonathan Zalevsky sold 3,867 shares of the business’s stock in a transaction on Tuesday, January 20th. The stock was sold at an average price of $35.67, for a total transaction of $137,935.89. Following the transaction, the insider directly owned 21,354 shares in the company, valued at $761,697.18. This trade represents a 15.33% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders have sold 4,470 shares of company stock valued at $181,955. Corporate insiders own 3.71% of the company’s stock.
Institutional Trading of Nektar Therapeutics
Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Emerald Mutual Fund Advisers Trust bought a new stake in shares of Nektar Therapeutics in the third quarter valued at about $13,269,000. Simplify Asset Management Inc. grew its position in Nektar Therapeutics by 67.6% during the third quarter. Simplify Asset Management Inc. now owns 87,174 shares of the biopharmaceutical company’s stock worth $4,960,000 after buying an additional 35,176 shares in the last quarter. Emerald Advisers LLC bought a new position in Nektar Therapeutics during the third quarter valued at about $18,393,000. Moody Aldrich Partners LLC increased its stake in Nektar Therapeutics by 62.3% during the third quarter. Moody Aldrich Partners LLC now owns 73,716 shares of the biopharmaceutical company’s stock valued at $4,194,000 after acquiring an additional 28,304 shares during the period. Finally, Farallon Capital Management LLC acquired a new position in Nektar Therapeutics in the 3rd quarter valued at approximately $45,008,000. 75.88% of the stock is currently owned by institutional investors and hedge funds.
Key Nektar Therapeutics News
Here are the key news stories impacting Nektar Therapeutics this week:
- Negative Sentiment: Rosen Law Firm reminds purchasers of NKTR securities of the May 5, 2026 lead plaintiff deadline in a class action covering Feb. 26–Dec. 15, 2025. ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Nektar Therapeutics Investors to Secure Counsel Before Important Deadline in Securities Class Action – NKTR
- Negative Sentiment: Pomerantz LLP says a class action was filed in the Northern District of California against Nektar and certain officers alleging violations of §§10(b) and 20(a) for the same class period. Pomerantz Law Firm Announces the Filing of a Class Action Against Nektar Therapeutics, Inc. and Certain Officers – NKTR
- Negative Sentiment: Robbins LLP alerts investors to the filed class action and encourages affected shareholders to contact the firm about recoveries for purchases during the stated class period. NKTR Stockholders Have Rights – If You Lost Money Investing in Nektar Therapeutics Contact Robbins LLP for Information About Recovering Your Losses
- Negative Sentiment: Glancy Prongay Wolke & Rotter posts a shareholder notice offering investors a chance to lead the securities fraud action and highlights the May 5 deadline. Nektar Therapeutics (NKTR) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
- Negative Sentiment: Bronstein, Gewirtz & Grossman announces a filed class action alleging investor harm for purchases during the same period. Bronstein, Gewirtz & Grossman LLC Urges Nektar Therapeutics Investors to Act: Class Action Filed Alleging Investor Harm
- Negative Sentiment: Bernstein Liebhard LLP and other firms issued shareholder alerts about the same securities-fraud filing and class period, urging investors to consider joining. SHAREHOLDER ALERT Bernstein Liebhard LLP Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against Nektar Therapeutics (NKTR)
- Negative Sentiment: The Schall Law Firm and Faruqi & Faruqi also issued notices reminding investors of the class action and the May 5 lead-plaintiff deadline. NKTR Investors Have Opportunity to Lead Nektar Therapeutics Securities Fraud Lawsuit with the Schall Law Firm
- Negative Sentiment: The Gross Law Firm issued a PR notice urging affected shareholders to contact them about seeking lead-plaintiff status in the securities lawsuit. NKTR Shareholder Alert: Investors With Losses May Seek to Lead the Class Action in Nektar Therapeutics Securities Lawsuit — The Gross Law Firm
About Nektar Therapeutics
Nektar Therapeutics (NASDAQ:NKTR) is a biopharmaceutical company dedicated to discovering and developing novel drug candidates through its proprietary chemistry and immunology platforms. The company focuses on polymer conjugate technology, which enables the creation of longer-acting versions of existing drugs, and on T-cell modulatory therapies aimed at harnessing the body’s immune system to treat cancer and other serious diseases.
Nektar’s product portfolio and pipeline include a range of clinical-stage and partnered programs.
See Also
Receive News & Ratings for Nektar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nektar Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
